0001193125-23-228613.txt : 20230905 0001193125-23-228613.hdr.sgml : 20230905 20230905165727 ACCESSION NUMBER: 0001193125-23-228613 CONFORMED SUBMISSION TYPE: 15-12G PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20230905 DATE AS OF CHANGE: 20230905 EFFECTIVENESS DATE: 20230905 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Apexigen, Inc. CENTRAL INDEX KEY: 0001814140 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 851260244 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 15-12G SEC ACT: 1934 Act SEC FILE NUMBER: 001-39488 FILM NUMBER: 231236618 BUSINESS ADDRESS: STREET 1: 900 INDUSTRIAL ROAD, SUITE C CITY: SAN CARLOS STATE: CA ZIP: 94070 BUSINESS PHONE: 650.931.6236 MAIL ADDRESS: STREET 1: 900 INDUSTRIAL ROAD, SUITE C CITY: SAN CARLOS STATE: CA ZIP: 94070 FORMER COMPANY: FORMER CONFORMED NAME: Brookline Capital Acquisition Corp. DATE OF NAME CHANGE: 20200603 15-12G 1 d876395d1512g.htm 15-12G 15-12G

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 15

 

 

CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION

UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934

OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTION 13 AND 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number: 001-39488

 

 

Apexigen, Inc.

(Exact name of registrant as specified in its charter)

 

 

900 Industrial Road, Suite C

San Carlos, CA 94070

(650) 931-6236

(Address, including, zip code and telephone number, including area code, of registrant’s principal executive offices)

Common Stock, par value $0.0001 per share

Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50 per share

(Title of each class of securities covered by this Form)

None

(Title of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

 

 

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

 

Rule 12g-4(a)(1)

   ☒

Rule 12g-4(a)(2)

   ☐

Rule 12h-3(b)(1)(i)

   ☒

Rule 12h-3(b)(1)(ii)

   ☐

Rule 15d-6

   ☐

Rule 15d-22(b)

   ☐

Approximate number of holders of record as of the certification or notice date: One.*

 

*

On August 23, 2023, pursuant to that certain Agreement and Plan of Merger, dated as of May 23, 2023, by and among Pyxis Oncology, Inc., a Delaware corporation (“Pyxis Oncology”), Apexigen, Inc., a Delaware corporation (“Apexigen”), and Ascent Merger Sub Corp., a Delaware corporation and wholly-owned subsidiary of Pyxis Oncology (“Merger Sub”), Merger Sub merged with and into Apexigen, with Apexigen surviving as a wholly-owned subsidiary of Pyxis Oncology.

Pursuant to the requirements of the Securities Exchange Act of 1934, Apexigen, Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

 

Date: September 5, 2023       Apexigen, Inc.
    By:  

/s/ Pam Connealy

     

Pam Connealy

Chief Financial Officer and Chief Operating Officer